Style | Citing Format |
---|---|
MLA | N Shayanfar NASRIN, et al.. "Cyclooxygenase-2 Overexpression and Its Association With Histopathological Features of Human Malignant Melanoma." Iranian Journal of Pathology, vol. 20, no. 2, 2025, pp. 190-199. |
APA | N Shayanfar NASRIN, Z Gholizade ZEINAB, F Montazer FATEMEH, K Kamyab KAMBIZ, A Nazari ARAM, Az Mirzaie Ali ZARE (2025). Cyclooxygenase-2 Overexpression and Its Association With Histopathological Features of Human Malignant Melanoma. Iranian Journal of Pathology, 20(2), 190-199. |
Chicago | N Shayanfar NASRIN, Z Gholizade ZEINAB, F Montazer FATEMEH, K Kamyab KAMBIZ, A Nazari ARAM, Az Mirzaie Ali ZARE. "Cyclooxygenase-2 Overexpression and Its Association With Histopathological Features of Human Malignant Melanoma." Iranian Journal of Pathology 20, no. 2 (2025): 190-199. |
Harvard | N Shayanfar NASRIN et al. (2025) 'Cyclooxygenase-2 Overexpression and Its Association With Histopathological Features of Human Malignant Melanoma', Iranian Journal of Pathology, 20(2), pp. 190-199. |
Vancouver | N Shayanfar NASRIN, Z Gholizade ZEINAB, F Montazer FATEMEH, K Kamyab KAMBIZ, A Nazari ARAM, Az Mirzaie Ali ZARE. Cyclooxygenase-2 Overexpression and Its Association With Histopathological Features of Human Malignant Melanoma. Iranian Journal of Pathology. 2025;20(2):190-199. |
BibTex | @article{ author = {N Shayanfar NASRIN and Z Gholizade ZEINAB and F Montazer FATEMEH and K Kamyab KAMBIZ and A Nazari ARAM and Az Mirzaie Ali ZARE}, title = {Cyclooxygenase-2 Overexpression and Its Association With Histopathological Features of Human Malignant Melanoma}, journal = {Iranian Journal of Pathology}, volume = {20}, number = {2}, pages = {190-199}, year = {2025} } |
RIS | TY - JOUR AU - N Shayanfar NASRIN AU - Z Gholizade ZEINAB AU - F Montazer FATEMEH AU - K Kamyab KAMBIZ AU - A Nazari ARAM AU - Az Mirzaie Ali ZARE TI - Cyclooxygenase-2 Overexpression and Its Association With Histopathological Features of Human Malignant Melanoma JO - Iranian Journal of Pathology VL - 20 IS - 2 SP - 190 EP - 199 PY - 2025 ER - |